Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT0LF7H)

DTT Name Fibroblast growth factor receptor (FGFR)
Synonyms FGF receptor
Gene Name NO-GeName
DTT Type
Successful target
 [1]
Related Disease
Bladder cancer [ICD-11: 2C94]
UniProt ID
NOUNIPROTAC
TTD ID
T17687

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Erdafitinib DMI782S Bladder cancer 2C94 Approved [2]
HIF-1alpha DM4OQRD Lymphoma 2A80-2A86 Phase 4 [1]
------------------------------------------------------------------------------------
8 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARQ-087 DM02BVQ Intrahepatic cholangiocarcinoma 2C12.10 Phase 3 [3]
BGJ398 DMNKBEC Cholangiocarcinoma 2C12.10 Phase 3 [3]
TAS-120 DMWM4D0 Cholangiocarcinoma 2C12.10 Phase 3 [4]
AZD4547 DM3827C Solid tumour/cancer 2A00-2F9Z Phase 2/3 [3]
BAY1163877 DMCSGJ2 Bladder cancer 2C94 Phase 2 [5]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
ICP-192 DM524GR Bladder cancer 2C94 Phase 2 [7]
PRN1371 DMR7BAO Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Clinical Trial Drug(s)
4 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARO 087 DMNAJQY Solid tumour/cancer 2A00-2F9Z Investigative [8]
PD173074 DMP0N4U Nasopharyngeal carcinoma 2B6B Investigative [1]
SU4984 DMWVN8R Discovery agent N.A. Investigative [1]
SU5403 DMV1408 Discovery agent N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
5 Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
6 The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
7 Clinical pipeline report, company report or official report of InnoCare Pharma.
8 J Clin Oncol 33, 2015 (suppl; abstr 2545).